NewsRoom Articles - Page 22 of 233

ThursdayAug 28, 2025 10:00 am

Study Explains Why Blood Clotting is Common in IBD Patients

About 3 million people in the U.S. live with irritable bowel disease (IBD), and its prevalence is rising. Unfortunately, there isn’t a cure for the condition at the moment. Many individuals with IBD develop clots in their blood and these can result in strokes and heart attacks. Now a new study has discovered possible reasons why these clots are common and suggests a possible way to address this problem while also reducing inflammation. The team, whose study author is Rebecca Mellema, explains that platelets in IBD patients are hyper-primed to clot at the smallest provocation. This is because the inbuilt…

WednesdayAug 27, 2025 12:00 pm

HeartBeam Inc. (NASDAQ: BEAT) Advances Patient Convenience with At-Home ECG Technology

Growing clinical evidence supports the expanding role of mobile and home-based ECG capture in improving patient outcomes. HeartBeam’s proprietary system offers a cable-free design that allows for high-fidelity ECG measurements without the complexity of conventional equipment. Portable, credit card-sized design enables patients to record symptoms at home or wherever they are. Clinicians are increasingly recognizing the value of accurate at-home electrocardiogram (“ECG”) capture, a development that is shaping the future of cardiac care. HeartBeam (NASDAQ: BEAT) is positioned at the forefront of this transformation with its FDA-cleared HeartBeam System, the first cable-free ECG device that captures the heart’s signals from 3 distinct…

TuesdayAug 26, 2025 12:00 pm

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Unveils Comprehensive Brand Identity Transformation to Position Company for Commercial Launch

The company's rebranding reflects Izotropic's refined corporate positioning and emphasizes its focus on key people across the healthcare ecosystem Izotropic's strategic positioning becomes even more critical when considering the magnitude of the opportunity ahead Izotropic has the exclusive global licensing rights to breast CT technology, and IzoView is the commercial model As Izotropic (CSE: IZO) (OTCQB: IZOZF) positions itself to capture a share of the $8.7 billion global breast imaging market projected by 2030 (ibn.fm/tRIr4), the company has unveiled a strategic brand transformation that signals its readiness to commercialize two decades of breakthrough medical research. Izotropic holds exclusive global licensing…

TuesdayAug 26, 2025 10:00 am

Blocking Glioblastoma-Triggered Brain Damage Could Slow the Aggressive Tumor’s Growth

According to new research conducted by a team at University College London, blocking the brain damage caused by glioblastoma could keep the patient’s brain working better for a much longer time and also slow the pace at which the tumor grows. The study used a mouse model and found that when glioblastoma tumors are in their early stage, they damage axons (parts of the nerves in the brain). When this damage occurs, according to the findings of the researchers, the brain responds to this injury to its nerve cells by first breaking down and then removing those damaged axons from…

TuesdayAug 26, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline

CEO reports confidence about late-stage rare disease pipeline and upcoming key development milestones. Soligenix’s recent accomplishments reflect substantial momentum across its specialized biotherapeutics and public health solutions business segments. The company's pipeline diversification strategy extends beyond CTCL treatment to encompass multiple therapeutic areas. With pivotal phase 3 cancer trial results due in 2026 and multiple fast-tracked therapies advancing through late-stage development, Soligenix (NASDAQ: SNGX) stands at the threshold of potentially transforming treatment paradigms for rare diseases affecting millions of underserved patients worldwide. The Soligenix pipeline includes a novel photodynamic drug therapy, along with other innovative drug and vaccine technology, to…

MondayAug 25, 2025 1:15 pm

Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements

Lantern Pharma completed enrollment in its LP-184 Phase 1a trial and is preparing Phase 1b/2 studies in cancers with large market potential. Early patient responses across LP-184, LP-284, and LP-300 trials highlight clinical activity in difficult-to-treat cancers. Intellectual property expanded with new European patent allowance for LP-284 and publication of blood-brain barrier prediction patent. Enhancements to RADR(R), the company’s AI platform, include public launch of predictBBB.ai(TM) and a new drug combination module. Lantern ended Q2 with $15.9 million in cash and expects its runway to extend into mid-2026. R&D expenses declined year-over-year, reflecting disciplined cost control while advancing multiple trials.…

FridayAug 22, 2025 12:00 pm

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

NRx Pharmaceuticals has filed a Citizen Petition with the FDA to remove benzethonium chloride from ketamine products. The preservative has known toxicity and is no longer allowed in hand sanitizers or topical antiseptics. Ketamine is increasingly used off-label for treating suicidal depression and PTSD. The company argues repeated exposure to benzethonium chloride through IV use poses unnecessary health risks. NRx has submitted data showing its preservative-free ketamine maintains sterility and stability for three years. The company is pursuing FDA approval for both its preservative-free ketamine (“NRX-100”) and oral NMDA-targeting drug (“NRX-101”). NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has…

FridayAug 22, 2025 10:00 am

Pioneering Therapy Could Slow the Effects of Aging

A new groundbreaking therapy could slow down or even reverse aging by recharging body cells with new “batteries” that provide new energy for bodily function. The new therapy utilizes mitochondria from the placenta of infants, which are then transplanted into older people or those suffering from diseases that are currently regarded as incurable. Minovia Therapeutics, a company based in Israel, is the first firm globally to test mitochondria transplantation in human beings as a way to help people remain younger for a longer time and also treat conditions that are regarded as incurable. Mitochondria are tiny organelles within cells, and…

ThursdayAug 21, 2025 12:45 pm

Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026

Clene Inc. plans to submit a New Drug Application (“NDA”) for lead candidate CNM-Au8® in ALS by year-end 2025. FDA meetings scheduled in Q3 2025 will address ALS survival benefit data and MS development plans. Neurofilament light biomarker data analysis from the NIH-sponsored EAP program is expected in early Q4 2025. The company reported $7.3 million in cash and cash equivalents as of June 30, 2025, together with recent financing extending the company’s cash runway into Q1 2026. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and…

ThursdayAug 21, 2025 10:00 am

Scientists Turn Bacteria into Trojan Horses to Deliver Anti-Cancer Viruses into Tumors

Scientists at Columbia University have engineered a cancer treatment that leverages bacteria to smuggle cancer-killing viruses into tumors in a method that sidesteps the defenses of the immune system. This groundbreaking approach utilizes two vital weapons against the cancer; the bacteria are drawn to cancer cells, and the viruses inside the bacteria deliver the killer blow to the tumor cells after being delivered there by the bacteria. The study team was successful in creating built-in safeguards intended to prevent the viruses from infiltrating and infecting tissues outside the tumor environment. Their research promises to introduce a new paradigm in the…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Study Explains Why Blood Clotting is Common in IBD Patients

HeartBeam Inc. (NASDAQ: BEAT) Advances Patient Convenience with At-Home ECG Technology

Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF) Unveils Comprehensive Brand Identity Transformation to Position Company for Commercial Launch

Blocking Glioblastoma-Triggered Brain Damage Could Slow the Aggressive Tumor’s Growth

Soligenix Inc. (NASDAQ: SNGX) Reports Major Clinical Trial Milestones, Strategic Progress in Rare Disease Treatment Pipeline

Lantern Pharma Inc. (NASDAQ: LTRN) Reports Q2 Results with Clinical Trial, AI Platform Advancements

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative

Pioneering Therapy Could Slow the Effects of Aging

Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026

Scientists Turn Bacteria into Trojan Horses to Deliver Anti-Cancer Viruses into Tumors

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search